Overview

Study Evaluating Mitoxantrone in Multiple Sclerosis

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to show the dose-response relationship of three doses of mitoxantrone with regard to efficacy in patients with secondary progressive multiple sclerosis and to show the safety and tolerability of mitoxantrone in these patients.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Mitoxantrone
Criteria
Inclusion Criteria:

- Secondary progressive MS in an active stage

- EDSS between 3 and 6

Exclusion Criteria:

- Benign or primary progressive MS

- Patients with cardiac risk factors

- Patients who have already received mitoxantrone